Short communication

Archives of Women's Mental Health

, Volume 6, Issue 2, pp 147-151

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response

  • T. PearlsteinAffiliated with Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • , E. SpurellAffiliated with Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • , L. A. HohlsteinAffiliated with Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • , V. GurneyAffiliated with Laurel Hill Inn Residential Eating Disorder Program, Medford, MA, U.S.A.
  • , J. ReadAffiliated with Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.
  • , C. FuchsAffiliated with Boston, MA, U.S.A.
  • , M. B. KellerAffiliated with Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A.

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

Keywords: Binge eating disorder; fluvoxamine; placebo.